While clinical data on the RANKL-blocking antibody denosumab suggests a potential relevance of RANK signaling in disease progression [17], its direct involvement in myeloma pathogenesis remains to be explored. The gene discussed is TNFRSF11A; the disease is plasma cell myeloma.